Some children with JRA/JIA can achieve long-term remission, with symptoms decreasing substantially over time. However, this does not mean the condition “goes away” in every case. The course depends on subtype: some forms are limited, while others can be persistent with fluctuating activity. Clinically, “going away” is better framed as remission—sustained low or absent disease activity. Achieving remission typically requires early diagnosis, regular monitoring, adherence to therapy, and supportive lifestyle measures. Stopping treatment without a clinician-guided plan can increase flare risk and contribute to joint damage. The most reliable pathway is treat-to-target management with controlled, monitored therapy adjustments.